Key facts
- It has raised $14.1M; the latest was Early Stage VC ($14.1M) in Dec 2025.
- Notable investors include Lenovo Capital and Incubator Group, Legend Star, Apricot Capital (Shanghai), Elikon Venture, Panlin Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Lync Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Lync Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lync Bio
Manufacturer of antibody-drug conjugates intended to advance therapies for autoimmune diseases and cancer. The company offers innovative drug research and clinical translation, enabling healthcare providers worldwide to address unmet patient needs.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2023
- Website
- lyncbio.com/
- Ownership
- Privately Held (backing)
Lync Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lync Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lync Bio in its N-PORT filings yet. We sweep new filings monthly.